Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10968337 | 0.81 | HDAC1 (0.40) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| SCHEMBL5603717 | 0.79 | — | — | |
| SCHEMBL5604064 | 0.77 | — | — | |
| SCHEMBL810202 | 0.76 | — | — | |
| SCHEMBL3778175 | 0.75 | CES2 (0.40) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| SCHEMBL28138809 | 0.75 | CES2 (0.40) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| SCHEMBL4940589 | 0.74 | HDAC1 (0.48) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| Methyl Alcohol SCHEMBL28109404 | 0.73 | CES2 (0.39) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| SCHEMBL3374389 | 0.72 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC8FFAR3 | |
| SCHEMBL1484027 | 0.72 | HDAC1 (0.46) | HDAC1HDAC2HDAC3HDAC8FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1174415-B1 | High purity preparation of fluorinated 1,3-dicarbonyls using BDM (bis-fluoroxydifluoromethane) | AIR PROD & CHEM (US) | 2003-10-22 | — | — | EP | claimed |
| EP-1174415-A1 | High purity preparation of fluorinated 1,3-dicarbonyls using BDM (bis-fluoroxydifluoromethane) | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2002-01-23 | — | — | EP | claimed |
| US-6307105-B1 | ELECTROPHILICALLY FLUORINATING A BETA-DICARBONYL WITH BIS(FLUOROXY)DIFLUOROMETHANE IN THE PRESENCE OF AN ACID | AIR PRODUCTS AND CHEMICALS, INC. | 2001-10-23 | — | — | US | claimed |
| US-10112973-B2 | Process for the preparation of ramipril | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-30 | — | — | US | disclosed |
| EP-3154940-B1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20170158733-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-06-08 | — | — | US | disclosed |
| CN-106661017-A | novel bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2017-05-10 | — | — | CN | disclosed |
| EP-3154940-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | Sanofi-Aventis Deutschland GmbH (DE) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189108-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-2549991-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | Vifor (International) AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| EP-1174415-B1 | High purity preparation of fluorinated 1,3-dicarbonyls using BDM (bis-fluoroxydifluoromethane) | AIR PROD & CHEM (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6455728-B1 | REACTING METHYL-3-OXOPENTANOATE WTIH HYDROGEN FLUORIDE IN PRESENCE OF OXYGEN; BY-PRODUCT INHIBITION; CHEMICAL INTERMEDIATES FOR PRODUCING PHARMACEUTICALS | AIR PRODUCTS AND CHEMICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1174415-A1 | High purity preparation of fluorinated 1,3-dicarbonyls using BDM (bis-fluoroxydifluoromethane) | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-0996606-B1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LTD (GB) | 2002-01-16 | — | — | EP | disclosed |
| US-6307105-B1 | ELECTROPHILICALLY FLUORINATING A BETA-DICARBONYL WITH BIS(FLUOROXY)DIFLUOROMETHANE IN THE PRESENCE OF AN ACID | AIR PRODUCTS AND CHEMICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6300511-B1 | FLUORINATING CARBONYL COMPOUND BY REPLACEMENT OF ALPHA-HYDROGEN ATOM WITH FLUORINE COMPRISING REACTING COMPOUND WITH FLUORINATING AGENT IN PRESENCE OF CATALYTICALLY EFFECTIVE AMOUNT OF TRANSITION METAL-CONTAINING CATALYST | F2 CHEMICALS LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-1095928-A2 | Direct fluorination process for preparing high purity alpha-fluoro-beta-dicarbonyl compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0996606-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 Chemicals Ltd. (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999003802-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112973-B2 | Process for the preparation of ramipril | CYP2S1, CYP3A5, CYP4B1 | HDAC1 2497/4885HDAC2 1294/4885HDAC3 1187/4885 |
| US-20170158733-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | CYP2S1, CYP3A5, CYP4B1 | HDAC1 2497/4885HDAC2 1294/4885HDAC3 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.